Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients

Neuropsychobiology

Volumn 54, Issue 4, 2007, Pages 226-230

  Saito, Shinichi ^a   Takahashi, Nagahide ^a   Ishihara, Ryoko ^a   Ikeda, Masashi ^a,b   Suzuki, Tatsuyo ^b   Kitajima, Tsuyoshi ^b   Yamanouchi, Yoshio ^b   Iwata, Nakao ^b   Yamada, Mitsuhiko ^c   Yoshida, Keizo ^a   Inada, Toshiya ^a,d   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Depressive disorder; Fluvoxamine response; Haplotype analysis; Vesicle associated membrane protein 2

Indexed keywords

BENZODIAZEPINE; FLUVOXAMINE; SYNAPTOBREVIN 2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEMI STRUCTURED INTERVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 34147117692     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100777     Document Type: Article

References (19)

1. Dalery J, Honig A: Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol 2003;18:379-384.
2. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.
3. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511.
4. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-386.
5. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B: Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001;303:119-122.
6. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136-140.
7. Serretti A, Artioli P: The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004;4:233-244.
8. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, Mueller JC, Lohmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319-1325.
9. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B: Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000;11:1893-1897.
10. Trimble WS, Cowan DM, Scheller RH: VAMP-1: a synaptic vesicle-associated integral membrane protein. Proc Natl Acad Sci U S A 1988;85:4538-4542.
11. Oyler GA, Higgins GA, Hart RA, Battenberg E, Billingsley M, Bloom FE, Wilson MC: The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations. J Cell Biol 1989;109:3039-3052.
12. Bennett MK, Calakos N, Scheller RH: Syntaxin: a synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones. Science 1992;257:255-259.
13. Weis WI, Scheller RH: Membrane fusion. SNARE the rod, coil the complex. Nature 1998;395:328-329.
14. Yamada M, Takahashi K, Tsunoda M, Nishioka G, Kudo K, Ohata H, Kamijima K, Higuchi T, Momose K: Differential expression of VAMP2/synaptobrevin-2 after antidepressant and electroconvulsive treatment in rat frontal cortex. Pharmacogenomics J 2002;2:377-382.
15. Williams JB: A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747.
16. Peveler R, Kendrick T: Selective serotonin reuptake inhibitors: THREAD trial may show way forward. BMJ 2005;330:420-421.
17. 2+ sensor for transmitter release at a central synapse. Cell 1994;79:717-727.
18. Motsinger AA, Lee SL, Mellick G, Ritchie MD: GPNN: Power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease. BMC Bioinformatics 2006;7:39.
19. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ: Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993;3:13-21.